Scinai Immunotherapeutics (SCNI) Retained Earnings (2016 - 2025)

Scinai Immunotherapeutics has disclosed Retained Earnings across 10 years of filings, most recently posting -$125.8 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$125.8 million, down 7.07% year-over-year; the trailing twelve-month figure through Dec 2025 was -$125.8 million (down 7.07% YoY), and the FY2025 annual result was -$125.8 million, down 7.07% from the prior year.
• Retained Earnings came in at -$125.8 million for Q4 2025 at Scinai Immunotherapeutics, down from -$121.7 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$413.0 in Q2 2022 to a low of -$345.0 billion in Q2 2021.
• The 5-year median for Retained Earnings is -$119.7 million (2023), against an average of -$37.8 billion.
• Across the five-year window, Retained Earnings jumped 100.0% in 2022 and sank 29809100.97% in 2023, its largest moves.
• Scinai Immunotherapeutics' Retained Earnings stood at -$110.0 million in 2021, then surged by 98.18% to -$2.0 million in 2022, then slumped by 5995.42% to -$122.3 million in 2023, then increased by 3.92% to -$117.5 million in 2024, then slipped by 7.07% to -$125.8 million in 2025.
• The last three Retained Earnings figures came in at -$125.8 million (Q4 2025), -$121.7 million (Q2 2025), and -$117.5 million (Q4 2024), per Business Quant data.